We at CanPharma are committed to provide patients with optimal medical care. In order to achieve this, not only do we supply pharmacies with high-quality medical cannabis, but together with our international network of partners and subsidiaries, we also concentrate on the complete research of the plant, its mode of action and potential, as well as advising and training doctors, pharmacists and patients.

You will find us in booth C12 in the exhibitors hall.

MEDICAL CANNABIS
www.auroramedicine.com

Bridging the Gap between Plant and Patients

We at CanPharma are committed to provide patients with optimal medical care.

In order to achieve this, not only do we supply pharmacies with high-quality medical cannabis, but together with our international network of partners and subsidiaries, we also concentrate on the complete research of the plant, its mode of action and potential, as well as advising and training doctors, pharmacists and patients.

You will find us in booth C12 in the exhibitors hall.
This programme book contains:

- Welcome Letter page 2
- General Information page 4
- Presidents & Coordinators page 8
- Poster Exhibition & Committees page 9
- Conference Programme page 13
- Friday’s Poster Presentations page 20
- Saturday’s Poster Presentations page 22
- Previous Events page 25
- IACM presents ... page 28
- Sponsoring Partners 2019 page 30
- Exhibition Hall page 34
- IACM Mission page 36
- IACM Memories page 38

Estrel Hotel Berlin, Germany
Dear colleagues and friends,

It is our pleasure to welcome you to Berlin for the IACM 10th Conference on Cannabinoids in Medicine.

The International Association for Cannabinoid Medicines (IACM) is a non-profit organization established in 2000, aiming to advance the knowledge on cannabis, cannabinoids, the endocannabinoid system and their therapeutic potential. Through various activities, we are strongly advocating for patients’ right to have legal access to cannabinoid medicines and for the right of doctors worldwide to be able to legally integrate cannabinoid medicines into their clinical practices.

In recent years we are all witnessing substantial changes, as regulatory frameworks for cannabinoid medicines are emerging globally. The therapeutic potential of cannabinoids for various symptoms and illnesses is now clearer than ever. Nevertheless, much effort is still needed to advance research on cannabinoids in order to facilitate evidence-based approaches and treatments. Indeed, this time in history is both exciting and challenging.

Our biennial conferences have grown substantially throughout the years, and we are privileged to continuously have world-class scientists and clinicians among our speakers and attendees. While we are committed to high scientific standards, we are additionally proud to have patients, as well as industry members, as integral associates within our organization and in this conference.
The current conference is covering the main aspects of research related to cannabinoids and the endocannabinoid system, presented by outstanding speakers. We are sure you will gain much knowledge and expertise during the coming days.

In this conference we are using Whova mobile application, in order to make it easier for you to navigate through the program, as well as to connect with one another for professional networking and for social activities. You are encouraged to download Whova to your mobile device in case you have not done so already, and to be involved in the vibrant online activities.

Finally, we wish to thank our sponsors for their support in this special event, and to each and every one of you who came from many countries around the globe to hear about the latest scientific discoveries, to meet with your peers and to be active members in our evolving community.

We wish you a successful meeting, and hope you will enjoy your stay in Berlin.

On behalf of the IACM Board of Directors, truly yours,

Manuel Guzman (1st Chairman)
Kirsten Müller-Vahl (2nd Chairwoman)
Franjo Grotenhermen (Executive Director)
Help-Desk @ Registration
If you need any help or guidance during the event, please reach out to our helping hands or the IACM eventmanagers at the location.

You recognize helping hand team members by their T-Shirt, they assist you in case you have questions, so please do not hesitate to ask.

Video & Photography
We would like to inform you that during this event photo and video recordings are taken, which are published in digital media and/or printed materials of the organizers. If you have any objection, please do not hesitate to contact us.

Simultaneous translation
There will be simultaneous translation from English into German on the First day. This is a tutorial day with reviews and practical information for physicians.

Evening Gala & IACM Awards on Saturday
A evening Gala on Saturday is included in the registration fee. During the meeting the IACM will honour four people for their major contributions to cannabinoid research and/or to the re-introduction of cannabis into modern medicine with the IACM Award. They will be presented with their award during the evening Gala on Saturday.
Your reliable and competent partner for Cannabidiol and Cannabinoids in B2B and B2C

medicalhemp.com

DEUTSCHES INSTITUT FÜR MEDIZINALCANNABIS
info@difmc.de
Conference Presidents

Franjo Grotenhermen
Nova Institute, Germany

Kirsten Müller-Vahl
Hannover Medical School
Hannover, Germany

Manuel Guzman
Complutense University
Madrid, Spain

Coordinators

Network Coordinator
Yuval Zolotov, Israel

Conference Coordinators
Lisa Katharina Haag
Maximilian Karau
PIONEERING THE FUTURE OF MEDICAL CANNABIS

TILRAY Product Portfolio:

- GMP-certified Production ensures pharmaceutical Quality
- CBD-Combination for a safe Therapy Start
- Broad Product Portfolio for a flexible Therapy

Full-spectrum Cannabis Extracts (different potencies)

Cannabis Dried Flower (different cultivars, potencies)
PERSONALIZING CANNABINOID CANCER TREATMENTS

# 3 Bethesda Metro Center
700 Bethesda, MD 20814
Phone: (877) 424-2429
info@cannabics.com
OTCQB:CNBX

medizinalhanf GmbH

Medizinische Qualität Partnerschaft Zuverlässigkeit

Deutscher lizenziertes pharmazeutischer Großhändler spezialisiert auf den Handel mit medizinischem Cannabis.

www.medizinalhanf.gmbh
contact@medizinalhanf.gmbh

CLINICAL TRIAL REGISTRY

Pure Green, a pharmaceutical grade medical cannabis company, is now accepting patient registration for the following indications:

- Chronic Pain
- Neuropathic Pain
- Menstrual Pain
- Sickle Cell Disease
- Chronic Pain After Surgical Procedures
- PTSD
- Anxiety
- Insomnia
- Pain from Autoimmune Diseases
- Post-Radiation Treatment Pain
- Migraine
- Opioid Reduction or Replacement

All studies are IRB (Institutional Review Board) approved and are free to patients.

We invite you to stop by the Pure Green booth #C2 to ask Dr. Kimless about our FDA Drug Development program and pick up a free gift.

www.pure.green

Debra Kimless, MD, Chief Medical Officer of Pure Green
Poster Exhibition

All posters should be placed on the boards during the whole conference.

Presenters of posters with odd numbers (1,3,5, etc.) are kindly requested to be present around their posters during Poster Session I (Friday, Nov. 1st, 12:30-14:30).

Presenters of posters with even numbers (2,4,6, etc.) are kindly requested to be present around their posters during Poster Session II (Saturday, Nov. 2nd, 12:30-14:30).

Please find the stand with your corresponding number or ask us for assistance.

<table>
<thead>
<tr>
<th>Organizing Committee</th>
<th>Scientific Committee</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ethan Russo</td>
<td>Franjo Grotenhermen</td>
</tr>
<tr>
<td>Franjo Grotenhermen</td>
<td>Kirsten Mueller-Vahl</td>
</tr>
<tr>
<td>Ilya Reznik</td>
<td>Roger Pertwee</td>
</tr>
<tr>
<td>Manuel Guzman</td>
<td>Ilya Reznik</td>
</tr>
<tr>
<td>Kirsten Mueller-Vahl</td>
<td>Manuel Guzman</td>
</tr>
<tr>
<td>Raquel Peyraube</td>
<td>Yuval Zolotov</td>
</tr>
<tr>
<td>Maximilian Plenert</td>
<td>Ethan Russo</td>
</tr>
<tr>
<td>Sebastien Beguerie</td>
<td></td>
</tr>
<tr>
<td>Yuval Zolotov</td>
<td></td>
</tr>
</tbody>
</table>
The Global Cannabis Company
A reliable supply partner for high-quality cannabis raw material at scale

Plena Global is a B2B cannabis production company supplying high-quality medical cannabis raw material to licensed producers, pharmaceutical companies, narcotic manufacturers and distributors worldwide.
100+ years of collective medical cannabis experience

3,200,000 sq. ft. licensed facility in Colombia

27,000,000 sq. ft. organic farm facility in development in Peru

500+ varietals in the seed bank and eligible for registration with ICA

“We are dedicated to producing a consistent and reliable global supply-chain for high-quality medical cannabis at scale so that our customers have the business certainty they need to meet their patient and customer demands.”
– Richard Zwicky, Chief Executive Officer

“The Plena Global team is driven every day by a shared commitment to ensure medical grade cannabis is accessible to those who require it in order to maintain, or improve, their quality of life.”
- Dr. Raquel Peyraube, Director of Public Policy and Health

“Plena Global’s focus is on scaling the production of high-quality medical cannabis by cultivating in strategic locations. Our farms in Colombia and Peru offer scalable land and optimal growing conditions.”
- Stefan Meyer, Chief Strategy Officer
NEW PATHS IN HEALTH
Thursday, 31 October 2019
„What we know: reviews and education“

REGISTRATION: 08:00 TO 17:00
OPENING: 08:35

08:35 - 08:50 Manuel Guzman (Spain)
  Conference Opening &
  Welcome by IACM Board

08:50 - 9:00 Günther Jonitz (Germany)
  President of the Medical
  Association of Berlin
  Opening Keynote
Thursday, 31 October 2019
„What we know: reviews and education“

REGISTRATION: 08:00 TO 17:00
OPENING: 08:35

09:00 - 09:45  Daniela Eigenmann  
(Switzerland)  
„History of medical cannabis“

09:45 - 10:30  Roger Pertwee  
(UK)  
„Pharmacological findings that reveal potential therapeutic uses for cannabinoids“

10:30 - 11:00  Coffee Break

11:00 - 11:45  Kirsten Müller-Vahl  
(Germany)  
„Effects of THC, CBD and cannabis: different or all the same?“

11:45 - 12:30  Ethan Russo  
(USA)  
„Cannabis: Where we are and where we're going“

12:30 - 14:00  Lunch Break
IACM Board & Ambassadors Meeting

Meeting of IACM board members, professional ambassadors and regulators from different countries

14:00 - 14:45  Ken Mackie (USA)
"An introduction to the endocannabinoid system"

14:45 - 15:30  Franjo Grotenhermen (Germany)
"Interactions & side-effects"

15:30 - 16:00  Coffee Break

16:00 - 16:30  Christian Kessler (Germany)
"Cannabis treatment under the legal situation in Germany"

16:30 - 18:00  Experts Panel (various countries)
"How to treat my first patient"
Friday, 1 November 2019

„What to discuss: controversies“

REGISTRATION: 08:15 TO 12:00
OPENING: 08:45

09:00 - 09:35 Ethan Russo (USA)
„Cannabis pharmacology: untapped potential“

09:35 - 10:10 Arno Hazekamp (Netherlands)
„The trouble with CBD-oil“

10:10 - 10:45 Ziva Cooper (USA)
„Cannabis and the opioid crisis“

10:30 - 11:15 Coffee Break

11:15 - 12:30 Oral Abstract Presentations (various countries)
Pt. 1 - 5 Presentations
15 minutes each

12:30 - 14:30 Lunch

Poster Session 1
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker</th>
<th>Country</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:30 - 15:05</td>
<td>Session 7: Controversies pt. 2</td>
<td>Bonni Goldstein</td>
<td>USA</td>
<td>„Cannabis for children: a pediatrician’s experience“</td>
</tr>
<tr>
<td>15:05 - 15:40</td>
<td></td>
<td>Ilya Retznik</td>
<td>Israel</td>
<td>„The medical use of cannabis in the elderly“</td>
</tr>
<tr>
<td>15:40 - 16:00</td>
<td>Coffee Break</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00 - 16:35</td>
<td></td>
<td>Mark Ware</td>
<td>Canada</td>
<td>„Update on cannabis and pain“</td>
</tr>
<tr>
<td>16:35 - 17:10</td>
<td></td>
<td>Attila Olah</td>
<td>Hungary</td>
<td>„Medical uses in dermatology“</td>
</tr>
<tr>
<td>17:10 - 18:15</td>
<td></td>
<td>Patients Panel</td>
<td>various countries</td>
<td>„Patients’ experiences“</td>
</tr>
<tr>
<td>19:00 - 22:00</td>
<td>Get together: invited sponsors &amp; the IACM board</td>
<td>Get together: invited sponsors</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Saturday, 2 November 2019

„Where to go: future directions“

REGISTRATION: 08:15 TO 12:00
OPENING: 08:45

09:00 - 09:35 Mario van der Stelt (Netherlands)
„The endocannabinoid system and its modulation“

09:35 - 10:10 Javier Fernández-Ruiz (Spain)
„Towards a cannabinoid-based neuroprotective therapy for neurodegenerative disorders“

10:10 - 10:45 Guillermo Velasco (Spain)
„Cannabis and cancer treatment“

10:30 - 11:15 Coffee Break

11:15 - 12:30 Oral Abstract Presentations (various countries)
Pt. 2 - 5 Presentations 15 minutes each

12:30 - 14:30 Lunch

Poster Session 2
**Gala-Dinner**

19:30 - 23:00

Gala Dinner with Award Ceremony and Jazz Trio at Estrel Hotel

---

**Session 11: Emerging new treatment options**

Chairs: Franjo Grotenhermen & Daniele Piomelli

14:30 - 15:05

Daniele Piomelli (USA)

„Potential clinical applications of endocannabinoid degradation inhibitors“

15:05 - 15:40

José Alexandre de Souza Crippa (Brazil)

„Cannabidiol in neuropsychiatry: Best leading or supporting actor?“

15:40 - 17:00

Experts Panel (various countries)

„What should clinicians, patients and regulators know? What questions are still waiting for an answer?“

17:00 - 17:15

Coffee Break

---

**IACM Membership Meeting**

17:15 - 18:00

General Meeting with IACM Members (other room - follow signs)

---

**Gala-Dinner**
<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:15</td>
<td>Clara Andradas Arias (Australia)</td>
<td>“CANNABINOIDS EFFECTIVELY BLOCK PROLIFERATION OF PAEDIATRIC MEDULLOBLASTOMA CELLS IN VITRO“</td>
</tr>
<tr>
<td>11:30</td>
<td>Kirsten Müller-Vahl (Germany)</td>
<td>“ABX-1431, A FIRST-IN-CLASS ENDOCANNABINOID MODULATOR, IMPROVES TICS AND THE URGE TO TIC IN ADULT PATIENTS WITH TOURETTE SYNDROME“</td>
</tr>
<tr>
<td>11:45</td>
<td>Addie Ron (Israel)</td>
<td>“MEDICAL CANNABIS FOR OLDER PATIENTS – TREATMENT PROTOCOL AND INITIAL RESULTS“</td>
</tr>
<tr>
<td>12:00</td>
<td>Vered Hermush (Israel)</td>
<td>“A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO INVESTIGATE THE EFFICACY &amp; SAFETY OF AVIDEKEL OIL FOR THE TREATMENT OF PATIENTS WITH AGITATION RELATED TO DEMENTIA“</td>
</tr>
<tr>
<td>12:15</td>
<td>Lihi Bar-Lev Schleider (Israel)</td>
<td>“CANNABIS INDUCES CLINICAL RESPONSE BUT NO ENDOSCOPIC RESPONSE IN CROHN’S DISEASE PATIENTS“</td>
</tr>
</tbody>
</table>
Dronabinol

Available by medical prescription in Germany and The Netherlands.

* Exporting worldwide, only to companies holding the corresponding import licenses.

Science Park 106 1098 XG Amsterdam The Netherlands
MYCB1.COM  INFO@MYCB1.COM

Fundación CANNA
Because we all have the right to know what we consume

Science and education on the cannabis plant

www.fundacion-canna.es
<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:15</td>
<td>Vincent Maida</td>
<td>&quot;TOPICAL MEDICAL CANNABIS-BASED MEDICINES (TCBM): A NEW EPIGENETIC PARADIGM FOR INTEGUMENTARY &amp; WOUND MANAGEMENT“</td>
</tr>
<tr>
<td>11:30</td>
<td>Philippe Lucas</td>
<td>&quot;CANNABIS SIGNIFICANTLY REDUCES THE USE OF OPIOIDS &amp; IMPROVES QUALITY OF LIFE IN PATIENTS; RESULTS OF A LARGE PROSPECTIVE STUDY“</td>
</tr>
<tr>
<td>11:45</td>
<td>George Habib</td>
<td>&quot;CHARACTERISTIC OF MEDICAL CANNABIS CONSUMPTION AMONG FIBROMYALGIA PATIENTS“</td>
</tr>
<tr>
<td>12:00</td>
<td>Albert Dahan</td>
<td>&quot;AN EXPERIMENTAL RANDOMIZED TRIAL ON THE ANALGESIC EFFECTS OF PHARMACEUTICAL-GRADE CANNABIS IN CHRONIC PAIN PATIENTS WITH FIBROMYALGIA“</td>
</tr>
<tr>
<td>12:15</td>
<td>Gwen Wurm &amp; Julia Arnsten</td>
<td>&quot;USE OF CANNABIS TO RELIEVE PAIN AND PROMOTE SLEEP BY CUSTOMERS AT AN ADULT USE DISPENSARY“</td>
</tr>
</tbody>
</table>

SATURDAY’S ORAL PRESENTATIONS

Chairs: Guillermo Velasco & Ilya Reznik
Global and Dynamic Support for the Cannabis Industry

PROPHARMA GROUP HAS THE KNOWLEDGE, EXPERTISE AND EXPERIENCE TO SUPPORT YOU IN:

- Import and export licenses
- Regulatory support
- Quality Compliance and Management
- Clinical, Product and Device Development

Our Vision is to revolutionize plant based healthcare for the 21st century.

phytolife.science
IS IT TIME TO START THINKING IN FULL COLOUR?

SUPPORT AND GUIDANCE ON INTEGRATING MEDICAL CANNABIS INTO YOUR PRACTICE.

Visit us at booth B5.
The International Association for Cannabinoid Medicines (IACM) was founded in March 2000.

The aim of the association is to **advance knowledge on cannabis, cannabinoids, the endocannabinoid system and related topics**, especially with regard to their therapeutic potential.

### Previous IACM events (2001 - 2017)

**Berlin, Germany**
- 1st IACM Conference on Cannabinoids (2001)

**Leiden, The Netherlands**
- 3rd IACM Conference on Cannabinoids (2005)

**Cologne, Germany**
- 4th IACM Conference on Cannabinoids (2007)
- 5th IACM Conference on Cannabinoids (2009)
- 7th IACM Conference on Cannabinoids (2013)
- 9th IACM Conference on Cannabinoids (2017)

**Bonn, Germany**
- 6th IACM Conference on Cannabinoids (2011)

**Sestri Levante, Italy**
- 8th IACM Conference on Cannabinoids (2015)
“This trio finds its origins in friendships and a common love for music. Kirk Lightsey (1937), probably the last great Post-Bop pianist, is a true poet and a unique creator. Darryl Hall’s (1963) versatility, soulfulness and openness have made him very much in demand. Adrien Varachaud (1977) was taught by Archie Shepp and Hal Singer, he likes to take risks and his game is full of openness and audacity. The programme will comprise original compositions and jazz standards.”
MEDICALLY APPROVED VAPORIZERS

ACCURATE TEMPERATURE SETTINGS

BIOAVAILABILITY 30 - 50%

NO COMBUSTION
Diamond

The Global Cannabis Company

Platinum

www.vapormed.com

IQANNA

Spectrum Therapeutics™
A CANOPY GROWTH COMPANY
Get the most out of the app and have a more productive experience at the IACM Cannabinoidconference2019!

1. **NAVIGATE** the event agenda and logistics, even without Wi-Fi or data. Access useful information like ridesharing and local attractions through the Community Board.

2. **NETWORK** effectively. Plan whom to meet by exploring attendee profiles and sending out messages.

3. **PARTICIPATE** in event activities through session likes, comments, ratings, live polling, tweeting, and more.
C1: Waters
C2: Pure Green
C3: Aurora
C4: IMCannabis
C5: MH Medical Hemp
C6: CC Pharma
C7: Aphria
C8: TBC.
C9: MYCB1
C10: Elite Healthcare Distribution
C11: German Institute for Medicinal Cannabis
C12: CanPharma
C13: Cannabics Pharmaceuticals
C14: THCPharm
C15: Bionorica ethics
C16: CBDepot
C17: ProPharma
C18: Four 20 Pharma

B1: Bedrocan
B2: Plena Global
B3: Tilray
B4: Storz & Bickel
B5: Spectrum by Canopy
B6: iQanna
The IACM mission is achieved in particular through the following actions:

1. Support for research into cannabis products and the endocannabinoid system;
2. Promotion of exchange of information between researchers, health care practitioners, patients and the public;
3. Preparation and dissemination of reliable information on the pharmacology, toxicology and therapeutic potential of cannabis and modulators of the endocannabinoid system;
4. Monitoring and documentation of national and international developments with respect to cannabinoid therapeutics;
5. Co-operation with other organisations and associations sharing the mission and goals of the IACM

With supporting the IACM, you support the association to fulfill our mission.
Over the past 25 years Bedrocan has developed unique methods of cultivating cannabis to pharmaceutical standards – a level achieved by no other company. Each product is standardised with a distinct chemical profile; a consistent, defined active ingredient composition, and is free of microbial contaminants, pesticides and heavy metals. The Bedrocan production facilities are GMP/API certified since 2017.

There should be a clear distinction between the medicinal and recreational use of cannabis. Patients and prescribers need for safe and consistent cannabis-based medicines is a priority”, founder and CEO Tjalling Erkelens says. He is convinced that this can be achieved by going through the formal drug approval process.

“Fully standardised pharmaceutical-quality cannabis is the foundation on which such approvals can be achieved.”
(-)-trans-Cannabidiol GMP (Cannabidiolum)
Active Substance for Pharmaceutical Use

Certifications: State Institute for Drug Control, Czechia suks 196923/2018 (EudraGMDP)

Substance of choice, public tender winner in 2017 and 2019, being supplied to pediatric hospital in Ljubljana / Slovenia for co-treatment of child epilepsy.

Broker: suks 29425/2018
CBDdepot, s.r.o., Masarykova 54, CZ-415 01 Teplice.
mail: info@cbdepot.eu, tel.: +421 905 853 870, fax: +421 43 5866 751
Cannabis and Hemp Testing
YOUR PARTNER FOR ANALYTICAL EXCELLENCE

www.waters.com/cannabis

ACM Hotline every Friday
for patients 11 am to 1 pm
3 pm to 5 pm

The patient telephone is a local
initiative by the IACM/ACM
„Arbeitsgemeinschaft Cannabis als
Medizin e.V.“

With supporting the IACM and
affiliated organisations, you
support local initiatives like this
to facilitate access to cannabis
as medicine.

Sie haben Fragen zur
Cannabinoid-Therapie?
Wir haben Antworten!

Besuchen Sie uns auf unserem Stand: C 15

Erfahren Sie mehr auf:
www.cannabinoid-colleg.de

Bionorica ethics GmbH
Kerschensteinerstr. 11-15
92318 Neumarkt
www.bionorica-ethics.de